|Day Low/High||83.92 / 85.05|
|52 Wk Low/High||64.18 / 86.14|
Wall Street ends a jampacked week little changed as a selloff in health care stocks counters broad gains elsewhere.
Fired former U.S. Attorney Preet Bharara was investigating stock trades made by Health and Human Services Secretary Tom Price, according to one report.
Stocks rise on Friday even as a selloff in health care extends into its second day.
Stocks creep lower on Friday as a selloff in health care extends into its second day.
- EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes
Jim Cramer says economic fundamentals remain strong and this market's rallying with relief at Fed's anticipated rate hike.
Despite all the prior failures and blowups, an Alzheimer's drug study -- no matter how unlikely to succeed -- remains an irresistible lure for some investors.
Doug Kass shares his thoughts on Allergan, and says that Caterpillar remains purr-fect for shorting.
Check out the latest versions of our Investment Indices and Core Holdings as well as 8 Bullpen additions.
Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.
Traders should look to go long on a close above $84.
Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.
Bull market number one, perhaps of all time: the financials.
Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'
Johna Norton will be replacing Fionnuala Walsh as senior VP of global quality.
Fionnuala Walsh retiring, Johna Norton promoted; Bart Peterson leaving to pursue external interests
Growth is not only about the occupant of the Oval Office, say Jim Cramer. This is a genuine bull market, and it's about how you invest.
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
Jim Cramer is opting for stocks like Allergan and Johnson & Johnson over Valeant Pharmaceuticals.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.
We'll sell our remaining shares in Panera and Costco to protect profits and move on.
Icahn may have a tough time finding interest in this behemoth.
Executives from 16 companies, including Boeing, Oracle and Pfizer, are weighing in to support the increasingly-contentious border adjustment tax